![ECOG-ACRIN logo[19516]275×75](https://blog-ecog-acrin.org/wp-content/uploads/2021/03/ECOG-ACRIN-logo19516275x75.png)
November 25, 2024
Several themes emerged as key areas of focus for ECOG-ACRIN during the Fall 2024 Group Meeting
August 14, 2024
A Scientific Member of ECOG-ACRIN since 2012
April 9, 2024
A new trial in glioblastoma; leadership transitions; upcoming Group Meeting highlights
April 9, 2024
Summaries of recently published ECOG-ACRIN research results
March 7, 2024
Big data projects near activation; APP Working Group builds momentum; ECOG-ACRIN welcomes Winn CILA scholar
March 7, 2024
Dr. Marshall's research focuses on the genetics of prostate cancer, as well as clonal hematopoiesis, a risk factor for cardiovascular disease that may be relevant to prostate cancer
February 9, 2024
In January, the medical community lost an acclaimed oncology physician, researcher, teacher, and health equity pioneer
December 19, 2023
The Fall 2023 Group Meeting was notable for a prominent increase in attention to diversity, equity, and inclusion
August 25, 2023
Summaries and links to timely information about research results in medical journals, recognition of research leaders, and more
April 19, 2023
Summaries and links to timely information about research results in medical journals, recognition of research leaders, and more
February 24, 2022
On the occasion of Black History Month, ECOG-ACRIN speaks with Edith Mitchell, MD about health equity and diversity initiatives within the Group
November 16, 2021
This pilot study is determining the feasibility and acceptability for adult and young adult participants patients between the ages of 18 and 39 in ECOG-ACRIN treatment trials to use the National Institutes of Health’s Patient-Reported Outcomes Measurement Information System (PROMIS®)